Sign up to our newsletter Subscribe
An Analysis of NICE’s Optimised Decisions from 2015 to 2024

Biosimilars have similar, but not identical, structures to branded biologic drugs. Being comparable, but not interchangeable, they can differ in cost-effectiveness and accessibility. Increased competition, however, can reduce healthcare system costs.